Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kasperkiewicz

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|May 10, 2024
Differing features of pemphigus in skin of colour versus white skin: A broad-scale cohort studyM Kasperkiewicz, N Elbuluk, B T Ngo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 16, 2021
COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid FoundationM Kasperkiewicz, M Yale, R Strong, et al.
The British Journal of Dermatology|March 13, 2010
Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisitaM Kasperkiewicz, M Hirose, A Recke, et al.
The British Journal of Dermatology|April 9, 2019
Clinical outcomes of patients with pemphigus treated by the same physicians in a public safety net healthcare system vs. a private healthcare systemM Kasperkiewicz, O Lai, A Recke, et al.
Clinical and Experimental Dermatology|June 25, 2009
Subacute cutaneous lupus erythematosus associated with terbinafineM Kasperkiewicz, W Anemüller, I Angelova-Fischer, et al.
The British Journal of Dermatology|September 12, 2012
Vitamin D status in patients with bullous pemphigoidS Tukaj, E Schmidt, A Recke, et al.
The British Journal of Dermatology|November 29, 2021
COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid FoundationM Kasperkiewicz, R Strong, K Mead, et al.
The British Journal of Dermatology|September 14, 2011
Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patientsM Kasperkiewicz, I Shimanovich, M Meier, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 26, 2020
Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemicM Kasperkiewicz, E Schmidt, J A Fairley, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 30, 2020
Expression of PD-1 and Tim-3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgarisN Ernst, M Friedrich, K Bieber, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of the European Academy of Dermatology and Venereology : JEADV|May 10, 2024
Differing features of pemphigus in skin of colour versus white skin: A broad-scale cohort studyM Kasperkiewicz, N Elbuluk, B T Ngo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 16, 2021
COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid FoundationM Kasperkiewicz, M Yale, R Strong, et al.
The British Journal of Dermatology|March 13, 2010
Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisitaM Kasperkiewicz, M Hirose, A Recke, et al.
The British Journal of Dermatology|April 9, 2019
Clinical outcomes of patients with pemphigus treated by the same physicians in a public safety net healthcare system vs. a private healthcare systemM Kasperkiewicz, O Lai, A Recke, et al.
Clinical and Experimental Dermatology|June 25, 2009
Subacute cutaneous lupus erythematosus associated with terbinafineM Kasperkiewicz, W Anemüller, I Angelova-Fischer, et al.
The British Journal of Dermatology|September 12, 2012
Vitamin D status in patients with bullous pemphigoidS Tukaj, E Schmidt, A Recke, et al.
The British Journal of Dermatology|November 29, 2021
COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid FoundationM Kasperkiewicz, R Strong, K Mead, et al.
The British Journal of Dermatology|September 14, 2011
Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patientsM Kasperkiewicz, I Shimanovich, M Meier, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 26, 2020
Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemicM Kasperkiewicz, E Schmidt, J A Fairley, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 30, 2020
Expression of PD-1 and Tim-3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgarisN Ernst, M Friedrich, K Bieber, et al.
Pageof 3